Bio-Hermes-002
Contify Life Sciences: Cognivue to Partner on Another Major Clinical Study with the Global Alzheimer’s Platform Foundation
Contify Life Science News Nov 3 • 11:52 PM *Cognivue’s participation in the study will help predict underlying AD pathologies and analyze MRI, neuroinflammation, and longitudinal data. Oct. 30– Cognivue issued the following news release:. Its proven ability to distinguish between cognitively normal individuals, those with MCI, and mild dementia— regardless of amyloid status., Validated […]
Read more »Precision Medicine Online: GAP Foundation Launches Second Study on Alzheimer’s Blood Biomarkers
Oct 30, 2024 | staff reporterSave for later NEW YORK – The Global Alzheimer’s Platform (GAP) Foundation has launched the Bio-Hermes-002 study, in which it will continue to explore biomarkers that can predict the likelihood that a patient has amyloid and tau accumulations in their brains, signaling a potential Alzheimer’s diagnosis. The Alzheimer’s research-focused nonprofit announced the […]
Read more »Collaborative effort to conduct a study aimed at improving the diagnosis of Alzheimer’s and related dementias for everyone
Global Alzheimer’s Platform Foundation Announces Strategic Partnerships for the Transformative Bio-Hermes-002 Study Washington D.C., Oct. 28, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These collaborations will enhance the unique, observational platform study that compares blood-based and digital biomarkers across a broad range […]
Read more »Gov.UK Notice: Dame Barbara Windsor Dementia Mission
What we do Dementia and Neurodegeneration was identified as one of the key healthcare missions in the 2021 Life Sciences Vision. Dementia is the leading cause of death in England and one in two people will be directly affected by it – either they will care for someone with the condition, develop it themselves, or both. […]
Read more »
PR Newswire: iLoF Secures $1.5M Clinical Research Contract to Deploy its Optomics® Platform in Leading International Alzheimer’s Study and Expands into the US
NEWS PROVIDED BYiLoF , Jul 31, 2024, 09:28 ET The international clinical study, Bio-Hermes-002, establishes an ambitious transnational collaboration aimed at achieving a breakthrough in Alzheimer’s diagnosis and treatment. LONDON and ROCHESTER, N.Y., July 31, 2024 /PRNewswire/ — iLoF, a global deep tech digital health company, today announced it has secured a £1.2M (~$1.5M) clinical research contract from Innovate UK, […]
Read more »
UK Research and Innovation: UK and US join forces to tackle dementia with innovative biomarkers
10 July 2024 Innovate UK has awarded four UK companies a share of £4 million funding through Contracts for Innovation to support innovative research into dementia diagnosis. The funding will enable organisations to evaluate blood-based and digital biomarkers as part of the Bio-Hermes-002 study. This international study is led by the Global Alzheimer’s Platform Foundation® […]
Read more »